DIRS.INFO The most relevant business & tech news

As the market continued to soar this month, hedge funds are betting against a handful of health-care and auto stocks. CNBC Pro used FactSet data to look for stocks trading on the New York Stock Exchange and Nasdaq Exchange with the most short interest as of Feb. 15. Here are the names of these heavily shorted stocks: Some health-care stocks saw a sizable increase in short interest. Biomea Fusion saw short interest increase by about 19% to 11.8 million shares, or about 43% of float. Children's Place saw short interest increase by more than 200% during the first half of February.

Organizations: Nasdaq, Dow Jones, CNBC, New York Stock Exchange, Nasdaq Exchange, Biomea, Traders, Children's, Mithaq Capital, Lucid Locations: Children's, Saudi

☆ Analysts love these biotech stocks, giving 4 more than 100% upside
▼ + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.

Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals

☆ 'A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks
▼ + stars: | 2024-01-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

2023 wasn't a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. But now, Citi believes that "astute investors may find themselves with a trove of rebound opportunities." Citi's top picks in biotech include Biomea Fusion , Alnylam Pharmaceuticals , and Immunovant . Jared Holz, health-care sector strategist at Mizuho Securities Americas, named biotech firm Biogen as one of his top trading ideas for 2024. "Biotech has commanded everyone's attention, but the recovery of many best-in-class medical device companies post the GLP-1 selloff has been remarkable," Orton said.

Persons: There's, Jared Holz, Biogen, Trent, medtech, Matt Orton, Orton Organizations: Citi Global Wealth Investments, U.S . Healthcare, Citi, Biomea, Alnylam Pharmaceuticals, Mizuho Securities Americas, Biogen, medtech, Raymond James Investment Management, Medical, Biotech, Abbott Laboratories Locations: U.S, Alphinity, medtech

☆ Citi is so bullish on this biotech stock it gives it 800% potential upside
▼ + stars: | 2023-11-29 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Citi is so bullish on one biotech firm that it has given its shares a target price that represents around 800% upside. In a Nov. 22 note, Citi gave the stock a buy rating and a price target of $90, representing potential upside of around 818% from Tuesday's price. However, the bank cautioned that the stock is high risk, given the "typical volatility" of biotech stocks and uncertainty associated with clinical trials. According to FactSet, analysts covering the stock give it average price target upside of 385% and a buy rating of 88%. On FactSet, the highest estimate came from Oppenheimer, which gives it potential upside of over 600%.

Persons: —, Oppenheimer, — CNBC's Michael Bloom Organizations: Citi, Citi isn't, BMO Capital Markets, BMO, P Biotech ETF, Biotech Locations: U.S

Search resuls for: "Biomea"

4 mentions found